Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
NICE has said Celgene's Vidaza (azacitidine) should not be funded by the National Health Service, estimating it costs the health system more than ten times as much as estimated by the manufacturer.
Under the deal, Celgene shareholders received $50 in cash plus a tradeable CVR for each share held, with the CVR entitling ...
UMB Financial plans to refile a $6.4 billion against Bristol-Myers Squibb by shareholders owning contingent value rights over its acquisition of Celgene. UMB plans to refile a lawsuit by the end ...
Evotec and Celgene partnered up in October 2017 to work on degenerative diseases, including Alzheimer’s. They signed a five-year agreement whereby Evotec received an upfront payment of €43m ...
Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Torres has teamed up with SHOW MORE OF YOU from Celgene and Otezla — a campaign that is shining light on the psoriasis or psoriatic arthritis. Torres was diagnosed with psoriasis in the middle ...
Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback